Immunotherapy of hematological malignancies: what is new?
نویسندگان
چکیده
منابع مشابه
Cellular immunotherapy as a beacon of hope for hematological malignancies
Recently, successful cancer immunotherapy has aroused great interest in application of this approach in hematological malignancies. Immune responsiveness is a key clinical feature of hematological malignancies. Indeed, the efficacy of allogeneic hematopoietic stem cell transplantation (HSCT) largely derives from graft-versus-tumor effects that highlight the ability of the immune system to speci...
متن کاملGenetically Modified T-Cell-Based Adoptive Immunotherapy in Hematological Malignancies
A significant proportion of hematological malignancies remain limited in treatment options. Immune system modulation serves as a promising therapeutic approach to eliminate malignant cells. Cytotoxic T lymphocytes (CTLs) play a central role in antitumor immunity; unfortunately, nonspecific approaches for targeted recognition of tumor cells by CTLs to mediate tumor immune evasion in hematologica...
متن کاملAllergen immunotherapy in asthma; what is new?
The use and role of allergen immunotherapy (AIT) in asthma is still a matter of debate, and no definite recommendation about this is made in guidelines, both for the subcutaneous and sublingual routes. This is essentially due to the fact that most controlled randomised trials were not specifically designed for asthma, and that objective measures of pulmonary function were only occasionally cons...
متن کاملCarbamazepine and Hematological Malignancies
Received/Geliş tarihi : May 1, 2013 Accepted/Kabul tarihi : June 10, 2013 To the Editor, The letter entitled “Carbamazepine and Multiple Myeloma: Possible Interaction”, written by Günaldı et al. [1] and published in one of the recent issues of your journal, was quite interesting. We would like to emphasize some points about that letter. In the reported case, the patient’s serum globulin level w...
متن کاملImmunotoxin therapy of hematological malignancies.
everal years have passed since the potential for unconjugated monoclonal antibodies (mAbs) to selectively target malignant cells was first described. Although the concept behind serotherapy is theoretically simple, the overall clinical results in these studies have often been disappointing and numerous obstacles have emerged due to the difficulty in penetrating tumor masses, the limited inheren...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Annals of Oncology
سال: 2005
ISSN: 0923-7534
DOI: 10.1093/annonc/mdi715